Challenges in the Diagnosis and Treatment of Growth Hormone Deficiency

Boston, MA US

Sunday, April 3, 2016 | 6:30 – 9:30 PM EST
Renaissance Boston Waterfront Hotel, Pacific Ballroom

This course is a live CME-certified ancillary symposium presented at ENDO 2016, the Endocrine Society's 98th Annual Meeting and Expo, held in Boston, Massachusetts, April 1–4, 2016. ENDO 2016 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC). There is no cost to attend, and all ENDO 2016 attendees are welcome; however, seating is limited and advance registration is recommended. You must be registered for ENDO 2016 to attend an ENDO 2016 ancillary symposium.

This activity is supported by an educational grant from Novo Nordisk Inc.

SYMPOSIUM AGENDA

Opening and Welcome
Program Director: Ken Ho, MD – Unviersity of Queensland (Australia)

Challenges and Current Controversies in Diagnosing Adult Growth Hormone Deficiency
Karen K. Miller, MD – Massachusetts General Hospital

Optimizing Response and Success in Growth Hormone Therapy: A Case-Based Approach to Initiating and Monitoring Treatment
Gudmundur Johannsson, MD, PhD – University of Gothenburg (Sweden)

Diagnosis and Management of GH Deficiency in Transition from Adolescence to Adulthood
Nelly Mauras, MD – Nemours Children's Health System

Moderated Panel Discussion and Audience Questions 

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists and endocrine fellows, pediatric endocrinologist and pediatric fellows and healthcare professionals who treat patients with growth hormone deficiency.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Use updated knowledge of the unique challenges in diagnosing growth hormone deficiency in adult patients to select and interpret biochemical tests
  • Select and/or optimize growth hormone therapy in growth hormone deficient adults taking patient needs and clinical outcomes into consideration
  • Evaluate the potential benefits and risks of growth hormone therapy in long-term management of growth hormone deficiency using up to date information
  • Summarize recent knowledge on the unique challenges in growth hormone therapy for pediatric patients including patient adherence, transition to adult care, and the study of long-term outcomes

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Quality Improvement and Healthcare Delivery
General Endocrinology
Growth Disorders
Neuroendocrinology and Pituitary
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation
Course opens: 
03/25/2016
Course expires: 
04/03/2017
Event starts: 
04/03/2016 - 6:30pm
Event ends: 
04/03/2016 - 9:30pm
Rating: 
0
Renaissance Boston Waterfront
606 Congress Street
Boston, MA 02210
United States

Ken Ho, MD – Program Director
Professor of Medicine, University of Queensland
Chair, Centres for Health Research
Princess Alexandra Hospital
Brisbane, Australia

Karen K. Miller, MD
Clinical Co-Director
Neuroendocrine Clinical Center
Massachusetts General Hospital
Boston, MA

Gudmundur Johannsson, MD, PhD
Professor of Endocrinology
Vice-Director, Department of Internal Medicine and Clinical Nutrition
Institute of Medicine
Sahlgrenska Academy, University of Gothenburg
Senior Consultant Department of Endocrinology
Gothenburg, Sweden

Nelly Mauras, MD
Chief, Division of Endocrinology
Nemours Children’s Health System
Professor of Pediatrics
Mayo College of Medicine
Jacksonville, Florida

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Nelly Mauras, MD: Principal Investigator, AstraZeneca, Genentech, Inc., Pfizer, Inc., Novartis Pharmaceuticals
Karen K. Miller, MD: Principal Investigator, Pfizer, Inc.

The following faculty reported no relevant financial relationship(s): Ken Ho, MD; Gudmundur Johannsson, MD, PhD

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:
John Carmichael, MD

The following SPC Committee members reported relevant financial relationships:
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme
Sarah Berga, MD: Advisory Board, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl Hirsch, MD: Consultant, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Valeritas; Investigator, Sanofi
E Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo E Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron

The following SPC members reported no relevant financial relationships:  Natalie Cusano, MD; Alan Kelly, MD; Larry Fox, MD; Michael S Irwig, MD; Connie B. Newman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation

Accreditation Period

Course opens: 
03/25/2016
Course expires: 
04/03/2017